-1 	|BT| (NP (NP (NP (JJ Inhibitory) (NN effect) (JJ oleanolic) (NN acid) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (NP (JJ ERK-p53-mediated) (NN cell) (NN cycle) (NN arrest)) (NP (JJ mitochondrial-dependent) (NN apoptosis)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 772:D02.455.849.919.530.733 773:G04.299.134.109|ES| 19:1 75:1 89:1 94:1 303:1 304:1 596:1 601:1 602:1 1275:1 2713:1 2714:1 2715:1 2716:1
-1 	|BT| (NP (NP (JJ Inhibitory) (NN effect) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 75:1 78:1 113:1 2533:1 2534:1 2635:1 2713:1
-1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
-1 	|BT| (S (NP (NP (JJ Kruppel-like) (NN factor) (CD 9)) (PRN (-LRB- -LRB-) (NP (NN KLF9)) (-RRB- -RRB-))) (VP (VBZ prevents) (NP (JJ colorectal) (NN cancer) (NN inhibition) (JJ interferon-related) (NN signaling)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 69:G02.111.087.800 617:D12.644.276.374.440 774:D12.776.124.125.375|ES| 10:1 14:1 17:1 18:1 19:1 103:1 185:1 195:1 318:1 703:1 2717:1 2718:1 2719:1
-1 	|BT| (S (NP (NN Latexin)) (VP (VBP exhibit) (NP (NN tumor) (NN suppressor) (JJ potential) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|104:C04.557.470.200.025.255 175:J01.897.280.500.269 206:G05.360.340.024.340.375.249|ES| 7:1 19:1 303:1 304:1 587:1 700:1 827:1 2720:1
-1 	|BT| (S (NP (NN Liver) (NN cell) (NN proliferation)) (VP (VBD increased) (ADVP (RB significantly)) (NP (NP (NN liver) (NN tumor) (JJ tamoxifen-treated) (NN rat)) (NP (ADJP (CD 12) (NN month)) (NN treatment) (NN recovery) (NN period))))) |ET| |BS|52:E02 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 775:E02.760.058 776:G01.910.645|ES| 7:1 19:1 47:1 94:1 124:1 299:1 546:1 836:1 849:1 1120:1 2721:1 2722:1 2723:1 2724:1 2725:1
-1 	|BT| (S (S (NP (JJ Liver-specific) (NN deletion) (NN prohibitin) (CD 1)) (VP (VBP result) (NP (JJ spontaneous) (NN liver) (NN injury)))) (, ,) (NP (NP (NN fibrosis)) (, ,) (NP (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 242:A03.620 306:G05.355.600.800 691:C23.550.355|ES| 2:1 19:1 52:1 98:1 101:1 283:1 303:1 304:1 836:1 949:1 1059:1 2416:1 2726:1 2727:1
-1 	|BT| (S (NP (NN Loss) (NN Dicer)) (ADVP (RB primarily)) (VP (VBZ impairs) (SBAR (S (NP (NN hepatocyte) (NN survival)) (VP (VBP promote) (NP (NN hepatocarcinogenesis) (NN cooperation) (JJ additional) (JJ oncogenic) (NN stimulus))))))) |ET| |BS|96:I03.784 262:A11.436.348 279:D27.888.569.100|ES| 19:1 274:1 679:1 900:1 953:1 980:1 1788:1 1909:1 1960:1 1970:1 2728:1 2729:1 2730:1
-1 	|BT| (S (NP (NN Loss) (NN metallothionein)) (VP (VBZ predisposes) (NP (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (VBG activating) (NN NF-kappaB) (NN target) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670|ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1
-1 	|BT| (S (NP (NNP Lycopene) (JJ active) (JJ chemopreventive) (NN agent) (NN offer) (NN protection) (JJ DEN-induced) (NN hepatocarcinogenesis)) (VP (VBG inhibiting) (NP (NN NF-kappaB) (NN mTOR) (NN pathway)))) |ET| |BS|122:C14.280.383 210:D12.776.260.600|ES| 19:1 197:1 383:1 714:1 728:1 880:1 900:1 1042:1 1946:1 2733:1 2734:1 2735:1 2736:1
-1 	|BT| (S (NP (NN Magnolol)) (VP (MD could) (ADVP (RB potentially)) (NP (JJ safe) (JJ potent) (JJ anticarcinogenic) (NN agent) (NN skin) (NN cancer)))) |ET| |BS|778:D27.505.954.444|ES| 18:1 19:1 22:1 333:1 728:1 773:1 908:1 2312:1 2319:1 2737:1
-1 	|BT| (S (NP (NN Melatonin)) (VP (VBD improved) (SBAR (S (NP (NN survival) (NN rate)) (VP (ADVP (RB successfully)) (VBD attenuated) (NP (NN liver) (NN injury))))) (, ,) (VP (VBN shown) (NP (NN histopathology))) (, ,) (VP (VBD decreased) (NP (NP (NN level) (NN serum) (NN transaminase)) (NP (VBN reduced) (NN expression) (JJ placental) (NN glutathione) (NN S-transferase)))))) |ET| |BS|242:A03.620 707:D03.438.473.914.481 779:E05.318.308.985.550.900 780:D08.811.913.225.500 781:D08.811.913.477.700 782:A12.207.152.846 783:A16.710|ES| 2:1 19:1 41:1 115:1 202:1 237:1 249:1 274:1 452:1 808:1 836:1 2410:1 2416:1 2738:1 2739:1 2740:1 2741:1 2742:1 2743:1 2744:1 2745:1
-1 	|BT| (S (NP (NN Metformin)) (VP (VBZ inhibits) (NP (JJ early) (NN stage) (JJ diethylnitrosamineinduced) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 784:D02.078.370.141.450|ES| 19:1 615:1 849:1 900:1 1128:1 1129:1 2746:1 2747:1
-1 	|BT| (NP (NP (NP (NN METHODOLOGY/PRINCIPAL) (NNS FINDINGS)) (: :) (NP (NP (JJ Pancreatic) (NN cancer) (NN cell) (NN line)) (VP (VBN treated) (NP (NN resveratrol)))))) |ET| |BS|52:E02 94:A11.251.210|ES| 18:1 19:1 94:1 104:1 264:1 1099:1 1213:1 1712:1 2748:1 2749:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (NP (NP (JJ UVB-induced) (NN skin) (NN carcinogenesis) (NN model) (NN SKH-1) (NN mouse)) (VP (VBN used) (S (VP (VBG determining) (NP (JJ preventive) (NN effect) (NN magnolol) (NN skin) (NN cancer) (NN development))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 168:E05.581 785:A17.815|ES| 18:1 19:1 35:1 52:1 72:1 75:1 104:1 207:1 476:1 565:1 1883:1 2319:1 2526:1 2750:1 2751:1 2752:1
-1 	|BT| (S (NP (NN Methyl) (NN antcinate) (NN A) (NN Antrodia) (NN camphorata)) (VP (VBZ induces) (NP (NP (NN apoptosis) (JJ human) (NN liver) (NN cancer) (NN cell) (JJ oxidant-mediated) (NN cofilin)) (: -) (NP (JJ Bax-triggered) (JJ mitochondrial) (NN pathway))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 573:N05.715.350.200.650 786:B01.300.179.120.174.070 787:D27.720.642|ES| 18:1 19:1 36:1 69:1 89:1 94:1 214:1 383:1 836:1 2004:1 2753:1 2754:1 2755:1 2756:1 2757:1 2758:1 2759:1
-1 	|BT| (NP (NP (NN Modulation) (NN energy) (JJ metabolic) (NN enzyme) (NN expression) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (JJ Chinese) (NN herb)) (, ,) (NP (NNP Huqi) (NNP San))) |ET| |BS|554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500|ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1
-1 	|BT| (FRAG (ADVP (RBR More) (RB importantly)) (, ,) (NP (NP (NN EPLE)) (VBN hampered) (NN tumor) (NN development) (NN CRC) (NN xenograft) (NN model))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 92:E04.936.764 93:A01.941.875|ES| 2:1 7:1 19:1 35:1 72:1 245:1 265:1 2489:1 2767:1 2768:1 2769:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (S (VP (VBG using) (NP (NP (NN mouse) (NN xenograft) (NN model)) (, ,) (NP (NN show) (NN treatment) (JJ specific) (NNP PPOX) (NN inhibitor) (NN acifluorfen))))) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NP (NP (NN growth) (CD three) (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 42.8) (NN %)) (-RRB- -RRB-))) (NN colon) (NN cancer) (NN line)) (NP (VBN investigated))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875|ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 102:1 113:1 124:1 264:1 265:1 350:1 369:1 380:1 403:1 429:1 452:1 482:1 540:1 546:1 622:1 1733:1 2770:1 2771:1 2772:1
-1 	|BT| (S (NP (NP (NNP Myrtenal)) (, ,) (NP (JJ natural) (NN monoterpene)) (, ,)) (VP (VBZ down-regulates) (SBAR (S (NP (NN TNF-alpha) (NN expression)) (VP (VBZ suppresses) (NP (JJ carcinogen-induced) (JJ hepatocellular) (NN carcinoma) (NN rat))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 351:A17.360 758:D02.455.849.575 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 19:1 115:1 303:1 304:1 686:1 849:1 2333:1 2421:1 2683:1 2773:1 2774:1 2775:1
-1 	|BT| (S (NP (NN N-acetyl-L-cysteine)) (VP (VBD blocked) (SBAR (S (NP (NN EGFR) (NN activation)) (VP (VBD reduced) (NP (JJ N-nitrosodiethylamine-initiated) (NN hepatocarcinogenesis) (NN level) (NNP Cre-Ctrl) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 554:D02.654.442.200 791:D02.886.030.230.259|ES| 19:1 52:1 187:1 225:1 249:1 452:1 900:1 2776:1 2777:1 2778:1 2779:1
-1 	|BT| (S (NP (JJ Natural) (NNS polyphenols)) (VP (VBP facilitate) (NP (NP (NN elimination) (NN HT-29) (JJ colorectal) (NN cancer) (NN xenograft) (NN chemoradiotherapy)) (: :) (NP (NP (NN Bcl-2)) (: -) (NP (NN superoxide) (NN dismutase) (JJ 2-dependent) (NN mechanism)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 56:D02.455.426.559.389.657.715 59:E02.186.079 92:E04.936.764 93:A01.941.875 792:A11.251.210.190.475|ES| 17:1 18:1 19:1 104:1 146:1 147:1 154:1 156:1 162:1 265:1 1989:1 2780:1 2781:1 2782:1 2783:1 2784:1
-1 	|BT| (S (NP (JJ Natural) (NN product) (NN pectolinarigenin)) (VP (VBZ inhibits) (NP (NN osteosarcoma) (NN growth) (NN metastasis)) (PP (IN via) (NP (JJ SHP-1-mediated) (NN STAT3) (NN signaling) (NN inhibition))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383 447:C04.557.450.565.575.650 793:D20.215|ES| 19:1 102:1 103:1 195:1 251:1 596:1 615:1 675:1 806:1 1562:1 2780:1 2785:1 2786:1
-1 	|BT| (S (NP (NN Nitidine) (NN chloride)) (VP (VBZ inhibits) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN cell)) (NN growth)) (NP (FW vivo) (NN suppression) (NN JAK1/STAT3) (NN signaling) (NN pathway)))) |ET| |BS|41:A11 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 122:C14.280.383 126:G02.111.087.800 794:D08.811.913.696.620.682.725.124.100|ES| 19:1 94:1 102:1 195:1 303:1 304:1 378:1 383:1 615:1 2453:1 2787:1 2788:1 2789:1
-1 	|BT| (NP (NP (NP (JJ Nitric) (JJ oxide-releasing) (NN aspirin) (NN indomethacin) (JJ potent) (NN inhibitor) (NN colon) (NN cancer) (JJ azoxymethane-treated) (NN rat)) (: :) (NP (NN effect) (JJ molecular) (NN target)))) |ET| |BS|52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420|ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1
-1 	|BT| (NP (NP (JJ Non-steroidal) (JJ anti-inflammatory) (NN drug) (NN sulindac) (JJ promising) (NN chemoprevention) (NN agent) (NN colon) (NN cancer)) (, ,) (NP (JJ weak) (NN potency) (NN side) (NN effect) (NN limit) (NN use) (NN chemoprevention) (NN chemotherapy))) |ET| |BS|151:E02.319 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500|ES| 2:1 18:1 19:1 75:1 113:1 191:1 338:1 495:1 728:1 869:1 870:1 871:1 1517:1 1659:1 2794:1 2795:1 2796:1 2797:1
-1 	|BT| (S (S (ADVP (RB Notably)) (, ,) (NP (JJ adeno-XAF1) (NN treatment)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN tumor) (NN growth)) (, ,) (ADVP (NP (ADJP (RB strongly) (VBN enhanced)) (NN antitumor) (NN activity) (NN TRAIL) (JJ gastric) (NN cancer) (NN xenograft) (NN model)) (FW vivo)) (, ,) (NP (RB significantly) (JJ prolonged) (NN survival) (NN time) (JJ animal) (NN bearing) (NN tumor) (NN xenograft))))) |ET| |BS|8:C04 19:B01.050 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875 96:I03.784 122:C14.280.383 322:G01.910 455:B01.050.150.900.649.147.890|ES| 2:1 7:1 18:1 19:1 46:1 72:1 86:1 102:1 124:1 265:1 274:1 365:1 378:1 385:1 399:1 546:1 635:1 1081:1 1584:1 1695:1 2244:1 2798:1 2799:1 2800:1
-1 	|BT| (S (ADVP (RB Notably)) (, ,) (NP (NN colon) (NN tumor) (NN prevention) (NN activity) (NN sulindac)) (VP (VP (VBN accompanied) (NP (NP (JJ marked) (NN induction) (JJ lymphoid) (NN aggregate)) (NP (JJ proximal) (JJ colonic) (JJ inflammatory) (NN mass) (NN lesion)))) (, ,) (VP (S (NP (JJ side) (NN effect)) (VP (VBN seen) (NP (JJR lesser) (NN degree) (NN celecoxib)))) (, ,) (NP (NN aspirin))))) |ET| |BS|51:C04.588.274.476.411.307.180 213:F02.830.816.964 251:D02.455.426.559.847.486.875 670:D02.455.426.559.389.657.410.595.176 684:D02.065.884.247 797:A10.549.600|ES| 2:1 7:1 19:1 75:1 113:1 399:1 677:1 724:1 736:1 869:1 871:1 1070:1 1131:1 1474:1 1967:1 2430:1 2487:1 2798:1 2801:1 2802:1 2803:1 2804:1 2805:1 2806:1 2807:1
-1 	|BT| (S (NP (JJ Nuclear) (NN Maspin) (NN expression)) (NP (ADJP (RB highly) (JJ predictive)) (NN 5-FU) (NN chemotherapy) (NN response) (NN patient)) (VP (VBD advanced) (NP (NN stage) (NN colon) (NN cancer)))) |ET| |BS|50:M01.643 151:E02.319 560:D03.383.742.698.875.404|ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1
-1 	|BT| (FRAG (PP (IN On) (NP (NN basis) (NN finding) (, ,) (NN development) (NN 2-aryl) (NN benzimidazole) (NN derivative))) (, ,) (NP (NP (JJ new) (NN class) (JJ multitarget) (JJ anticancer) (NN agent)) (, ,) (VP (VBD warranted) (VP (VBZ represents) (NP (NP (JJ novel) (NN strategy)) (VP (VBG improving) (NP (NN breast) (NN cancer) (NN treatment)))))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 660:D27.505.954.248 798:D03.438.103|ES| 2:1 18:1 19:1 23:1 35:1 546:1 712:1 728:1 891:1 927:1 1114:1 1140:1 1880:1 2363:1 2516:1 2810:1 2811:1 2812:1 2813:1 2814:1 2815:1 2816:1
-1 	|BT| (S (NP (ADJP (RB Orally) (VBN administered)) (NN lycopene)) (VP (VBZ attenuates) (NP (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN rat)) (VP (VBG modulating) (NP (NP (NN Nrf-2)) (: /) (NP (NN HO-1) (NN Akt/mTOR) (NN pathway))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534|ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD indicated) (SBAR (S (NP (NN nifuroxazide)) (VP (MD may) (ADVP (RB potentially)) (NP (JJ therapeutic) (NN agent) (NN growth) (NN metastasis) (NN breast) (NN cancer))))))) |ET| |BS|52:E02 113:C04.697.650|ES| 18:1 19:1 23:1 102:1 491:1 541:1 658:1 728:1 773:1 793:1 806:1 1541:1 2820:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD indicated) (NP (NP (NN silymarin) (JJ therapeutic) (NN effect)) (NP (JJ early) (NN stage) (NN liver) (NN damage))) (, ,) (S (VP (VBG reversing) (NP (NP (JJ fatty) (NN change)) (VP (VBG recovering) (NP (NN liver) (NN histopathology) (JJ dose-dependent) (NN manner)))))))) |ET| |BS|242:A03.620 801:D03.383.663.283.266.450.268.777|ES| 2:1 19:1 75:1 200:1 541:1 658:1 793:1 836:1 1128:1 1129:1 1541:1 1668:1 1848:1 2070:1 2740:1 2821:1 2822:1 2823:1 2824:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (ADVP (RB thus)) (VP (VBP establish) (SBAR (S (NP (NN EPLE) (JJ novel) (NN inhibitor) (NN Wnt) (NN signaling)) (VP (VBP hold) (NP (JJ great) (NN promise) (JJ potential) (NN candidate) (JJ preclinical) (NN evaluation) (NN CRC) (NN treatment))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 69:G02.111.087.800 225:E05.337 259:D12.776.395.240.150.500|ES| 19:1 195:1 220:1 245:1 380:1 546:1 658:1 793:1 827:1 877:1 891:1 1243:1 1334:1 1494:1 2489:1 2503:1 2825:1 2826:1 2827:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data) (NN pterostilbene)) (VP (VBG suppressing) (NP (NP (NN colon) (NN tumorigenesis)) (, ,) (NP (NN cell) (NN proliferation)) (NP (ADJP (RB well) (JJ key)) (JJ inflammatory) (NN marker))) (ADVP (FW vivo) (FW vitro)) (VP (VBP suggest) (NP (JJ potential) (NN use) (NN pterostilbene) (NN colon) (NN cancer) (NN prevention))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 158:D23.101 183:G04.299.233.750|ES| 2:1 18:1 19:1 78:1 94:1 113:1 159:1 216:1 299:1 378:1 534:1 658:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (ADVP (RB also)) (VP (VBD showed) (SBAR (S (NP (NP (JJ myrtenal) (NNS restrains) (NN liver) (NN cancer)) (VP (VBG preventing) (NP (NN DEN-PB)))) (VP (VBD induced) (NP (NN up-regulation) (NN TNF-alpha) (NN protein) (NN expression) (NN immunoblot))))))) |ET| |BS|7:D12.776 122:C14.280.383 142:I01.880.604 789:D12.644.276.374.500.800 790:D12.644.276.374.750 802:E05.478.566.320|ES| 4:1 5:1 18:1 19:1 115:1 132:1 412:1 658:1 836:1 896:1 927:1 1937:1 2682:1 2775:1 2828:1 2829:1 2830:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (NP (NN rimonabant) (ADJP (JJ able) (S (VP (VBP inhibit) (NP (NP (JJ colorectal) (NN cancer) (NN cell) (NN growth) (JJ different) (NN stage) (NN colon) (NN cancer) (NN pathogenesis)) (VP (VBG inducing) (NP (JJ mitotic) (NN catastrophe) (NN vitro)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 122:C14.280.383 385:F02.784.629.131|ES| 17:1 18:1 19:1 94:1 102:1 113:1 216:1 414:1 501:1 658:1 720:1 796:1 927:1 1129:1 1370:1 1864:1 2831:1 2832:1 2833:1
-1 	|BT| (S (NP (PRP$ Our) (JJ present) (NN study)) (VP (VBP identify) (S (NP (NP (JJ chemopreventive) (JJ potential) (NN pterostilbene) (JJ colonic) (NN tumor) (NN formation)) (NN end) (NN point)) (VP (VB evaluate) (NP (JJ mechanistic) (NN action) (NN pterostilbene) (NN colon) (NN carcinogenesis)))))) |ET| |BS|20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 225:E05.337 742:G03.787|ES| 7:1 19:1 43:1 113:1 131:1 207:1 658:1 677:1 827:1 832:1 890:1 1307:1 1890:1 1946:1 2013:1 2121:1 2428:1 2834:1
-1 	|BT| (S (NP (PRP$ Our) (JJ previous) (NN study)) (VP (VBD demonstrated) (SBAR (S (NP (NP (JJ garlic) (NN oil)) (PRN (-LRB- -LRB-) (NP (NN GO)) (-RRB- -RRB-))) (VP (MD could) (VP (VB prevent) (NP (JJ NDEA-induced) (NN hepatocarcinogenesis) (NN rat)) (, ,) (NP (NP (VBG underlying) (NN mechanism)) (VP (ADVP (RB fully)) (VBN understood))))))))) |ET| |BS|239:F02.463.188.357 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 131:1 162:1 435:1 658:1 733:1 849:1 889:1 900:1 908:1 979:1 1175:1 1819:1 2614:1 2835:1 2836:1 2837:1
-1 	|BT| (S (PRP$ Our) (VP (VBP result) (ADVP (RB clearly)) (VP (VBP indicate) (SBAR (S (NP (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (VBD exert) (NP (JJ marked) (NN chemoprevention) (JJ DENA-initiated) (NN hepatocarcinogenesis) (NN inhibition) (JJ abnormal) (NN cell) (NN proliferation) (NN induction) (NN apoptosis)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 253:E02.319.162 554:D02.654.442.200 803:D01.248.497.158.845 804:D09.698|ES| 19:1 89:1 94:1 101:1 103:1 299:1 658:1 736:1 870:1 900:1 1229:1 1479:1 2802:1 2838:1 2839:1 2840:1 2841:1 2842:1 2843:1 2844:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP demonstrate)) (, ,) (NP (ADVP (JJ first) (NN time)) (, ,) (NP (NP (NP (ADJP (NN elaiophylin) (JJ novel)) (NN autophagy) (NN inhibitor)) (, ,) (NP (NP (JJ significant) (NN antitumor) (NN efficacy)) (JJ single) (NP (NN agent) (NN combination) (JJ human) (JJ ovarian) (NN cancer) (NN cell)))) (, ,) (VP (VBG establishing) (NP (JJ potential) (NN treatment) (JJ ovarian) (NN cancer) (NN compound)))))))) |ET| |BS|41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 259:D12.776.395.240.150.500 322:G01.910 390:G04.299.139.399 660:D27.505.954.248 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 2:1 18:1 19:1 36:1 94:1 101:1 135:1 380:1 502:1 530:1 546:1 658:1 728:1 816:1 827:1 891:1 1081:1 1317:1 1763:1 2244:1 2304:1 2433:1 2845:1 2846:1 2847:1
-1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (SBAR (S (NP (NNP Lrat) (NNP KO) (NN mouse)) (NP (DT le) (JJ susceptible) (JJ DEN-induced) (NN hepatocarcinogenesis)) (ADVP (RB due)) (VP (VBD increased) (NP (ADJP (NP (NN retinoid) (NN signaling)) (JJR higher)) (NN expression) (NN p21)) (, ,) (SBAR (S (NP (NP (VBN accompanied) (JJ altered) (JJ hepatic) (NN level)) (JJ DEN-activating) (NN enzyme) (NNP MGMT) (NNP Lrat) (NNP KO) (NN mouse)) (ADVP (RB also)) (VP (VBP contribute) (SBAR (S (NP (VBN decreased) (NN cancer) (NN initiation)) (VP (VBD suppressed) (NP (NN liver) (NN tumor) (NN development))))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 515:C04.588.274.623 649:E01.370.225.124.200 711:D02.455.326.271.665.202.495 807:D08.811.913.555.500.800.650|ES| 2:1 5:1 7:1 18:1 19:1 35:1 47:1 52:1 101:1 115:1 170:1 195:1 202:1 249:1 307:1 450:1 637:1 658:1 693:1 836:1 838:1 899:1 900:1 1135:1 1479:1 2388:1 2573:1 2735:1 2801:1 2848:1 2849:1 2850:1 2851:1 2852:1 2853:1
-1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (SBAR (S (NP (NP (NN administration) (NN resveratrol)) (UCP (CC either) (NP (JJ early) (JJ advanced) (NN stage) (NN hepatocarcinogenesis)) (ADJP (RB equally) (JJ effective)))) (VP (VBZ involves) (NP (NP (NN activation)) (NP (JJ apoptotic) (NN pathway) (NN male) (NNP Wistar) (NN rat)))))))) |ET| |BS|39:G04.299.139.160 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 39:1 101:1 225:1 383:1 658:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1479:1 1639:1 1673:1 1712:1 2223:1 2575:1 2603:1 2854:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (NP (NN show) (NN enzastaurin) (JJ effective) (JJ chemopreventive) (NN agent) (NN mouse) (NN model) (JJ sporadic) (NN colon) (NN cancer)) (SBAR (S (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (NN expression) (JJ proproliferative) (NN gene)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 16:C23.550.291.656 122:C14.280.383 155:G05.355.310|ES| 7:1 9:1 18:1 19:1 48:1 52:1 72:1 101:1 113:1 115:1 124:1 142:1 429:1 637:1 658:1 725:1 728:1 880:1 1639:1 1946:1 2855:1 2856:1
-1 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (NP (NN cimetidine) (VBG inhibiting) (NN effect) (NN hepatocarcinogenesis)))) |ET| |BS|12:Z01.542.049 122:C14.280.383 808:D02.078.370.200|ES| 19:1 75:1 101:1 132:1 658:1 880:1 900:1 2857:1
-1 	|BT| (S (NP (PRP$ Our) (NN study)) (VP (VBZ demonstrates) (NP (NP (NN inhibition) (NN cell) (NN proliferation) (NN regulation)) (SBAR (S (NP (JJ inflammatory) (NN marker)) (VP (MD may) (, ,) (ADVP (JJS least) (NN part)) (, ,) (S (VP (VBG underlying) (NP (NN mechanism) (JJ related) (NN liver) (NN tumor) (NN inhibition) (NN diosmin)))))))))) |ET| |BS|41:A11 43:F01.145.544 85:G02.111.087.225 158:D23.101 183:G04.299.233.750 515:C04.588.274.623 715:D03.383.663.283.266.450.260.222|ES| 2:1 7:1 19:1 94:1 103:1 131:1 162:1 299:1 419:1 435:1 438:1 451:1 491:1 534:1 658:1 836:1 1331:1 2430:1 2541:1 2695:1
-1 	|BT| (S (NP (JJ Overall) (NN finding)) (VP (VBP substantiate) (SBAR (S (NP (NN artesunate)) (VP (VBZ promotes) (SBAR (S (NP (JJ anti-tumour) (, ,) (JJ anti-proliferation) (NN apoptosis) (NN nitrosodiethylamine)) (VP (VBD mediated) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500|ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1
-1 	|BT| (SINV (S (NP (JJ Overall) (NN analysis)) (VP (VBD indicated) (SBAR (S (NP (NN pterostilbene)) (VP (VBD reduced) (NP (NN colon) (NN tumor) (NN multiplicity) (JJ non-invasive) (NN adenocarcinoma))))))) (, ,) (VP (VBD lowered) (S (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen))))) (VP (VBD downregulated) (NP (NN expression) (NN beta-catenin) (NN cyclin) (NN D1)))) |ET| |BS|23:D12.776.091.249 51:C04.588.274.476.411.307.180 84:C04.557.470.200.025 215:D12.644.360.262.150.100 696:V02.270.500 768:D12.776.660.740|ES| 2:1 7:1 19:1 60:1 94:1 113:1 115:1 255:1 426:1 452:1 661:1 743:1 744:1 1030:1 1256:1 1361:1 1541:1 2428:1 2858:1 2863:1 2864:1 2865:1
-1 	|BT| (S (ADVP (RB Overall)) (, ,) (VP (VBP result) (NP (NN support) (JJ translational) (JJ potential) (NN silibinin) (JJ colorectal) (NN cancer) (NN chemoprevention)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 145:G02.111.087.675.871 253:E02.319.162 696:V02.270.500 809:L01.178.682.920|ES| 2:1 17:1 18:1 19:1 101:1 827:1 870:1 1364:1 2635:1 2858:1 2866:1
-1 	|BT| (S (NP (NN Overexpression) (NN Klotho)) (VP (VBZ suppresses) (SBAR (S (NP (NN liver) (NN cancer) (NN progression)) (VP (VBZ induces) (S (NP (NN cell) (NN apoptosis)) (ADVP (RB negatively)) (VP (VBG regulating) (NP (JJ wnt/beta-catenin) (NN signaling) (NN pathway))))))))) |ET| |BS|16:C23.550.291.656 39:G04.299.139.160 41:A11 105:G02.149.115.800.925|ES| 18:1 19:1 48:1 89:1 94:1 195:1 214:1 383:1 668:1 686:1 836:1 2867:1 2868:1 2869:1 2870:1
-1 	|BT| (S (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma)) (VP (VBZ contributes) (NP (JJ inhibitory) (NN effect) (NN Embelin) (NN colon) (NN carcinogenesis)))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 719:D12.776.826.239.588|ES| 19:1 75:1 113:1 207:1 845:1 1800:1 1801:1 2429:1 2587:1 2871:1
-1 	|BT| (NP (NP (NP (JJ Pharmacogenetic) (NN approach) (NN capecitabine) (NN 5-fluorouracil) (NN selection)) (SBAR (S (NP (VBN combined) (NN oxaliplatin) (JJ first-line) (NN chemotherapy)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 151:E02.319 375:Z01.639.100 560:D03.383.742.698.875.404 810:D03.383.742.680.245.500.425 811:H01.158.273.343.750 812:G05.355.800|ES| 17:1 18:1 19:1 164:1 495:1 911:1 997:1 2307:1 2490:1 2543:1 2872:1 2873:1 2874:1
-1 	|BT| (S (NP (NN Phyllanthus) (NN urinaria)) (VP (VBZ ameliorates) (NP (NN severity) (JJ nutritional) (FW steatohepatitis) (FW vitro) (FW vivo)))) |ET| |BS|508:C06.552.241 813:B01.650.940.800.575.100.350.622|ES| 19:1 216:1 378:1 1473:1 1791:1 2875:1 2876:1 2877:1 2878:1
-1 	|BT| (S (NP (NN Polyenephosphatidylcholine)) (VP (VBZ prevents) (NP (NP (JJ alcoholic) (NN liver) (NN disease) (NN PPARalpha-null) (NN mouse) (NN attenuation) (NN increase)) (JJ oxidative) (NN stress)))) |ET| |BS|29:B01.050.050.136.500.500 536:D12.776.826.239.500 716:G03.495.710 814:C06.552.645|ES| 19:1 40:1 52:1 836:1 998:1 2522:1 2583:1 2718:1 2879:1 2880:1 2881:1 2882:1
-1 	|BT| (S (NP (NP (NP (JJ Polyinosinic-polycytidylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN Poly) (NN I) (: :) (NN C)) (-RRB- -RRB-))) (NN IFN-gamma) (NN treatment)) (VP (VBD inhibited) (NP (NN liver) (NN fibrosis) (JJ pair-fed) (JJ ethanol-fed) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 122:C14.280.383 663:C16.320.565.398.500.330.500 676:C06.552.630 751:D02.033.375 815:D13.695.578.550.560.600 816:G01.358.500.505.300|ES| 10:1 14:1 19:1 52:1 104:1 365:1 546:1 836:1 949:1 1275:1 1955:1 2350:1 2883:1 2884:1 2885:1 2886:1 2887:1
-1 	|BT| (NP (NP (NP (NP (NP (NP (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (: -))) (-RRB- -RRB-) (NN mouse) (JJ susceptible) (JJ DMH-induced) (NN colon) (NN carcinogenesis) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NN mouse))) (, ,) (S (NP (NN embelin)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NP (NN incidence) (NN colon) (NN cancer) (NN PPARgamma)) (PRN (-LRB- -LRB-) (NP (NP (CC +) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (: -))) (-RRB- -RRB-))) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 434:E05.318.308.985.525.375 719:D12.776.826.239.588|ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 124:1 207:1 452:1 899:1 1511:1 2588:1 2888:1 2889:1
-1 	|BT| (S (NP (NNP Pravastatin)) (VP (VBZ reduces) (NP (NN lung) (NN metastasis) (NN rat) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (VBN coordinated) (NN decrease) (NN MMP) (NN expression) (NN activity))))) |ET| |BS|104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 817:D02.455.426.559.847.638.930 818:D08.811.277.656.300.480.525|ES| 19:1 115:1 142:1 295:1 303:1 304:1 328:1 399:1 596:1 806:1 849:1 2890:1 2891:1 2892:1
-1 	|BT| (S (NP (JJ Preclinical) (JJ clinical) (NN investigation)) (VP (VBP demonstrate) (SBAR (S (NP (NN aspirin)) (VP (VBP inhibit) (NP (NP (JJ several) (NN type) (NN cancer) (JJ colorectal) (NN adenoma) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))))) |ET| |BS|17:C04.557.470.035 104:C04.557.470.200.025.255 122:C14.280.383 225:E05.337 670:D02.455.426.559.389.657.410.595.176|ES| 10:1 14:1 17:1 18:1 19:1 42:1 84:1 262:1 303:1 304:1 441:1 502:1 543:1 1370:1 1497:1 2487:1 2893:1
-1 	|BT| (S (NP (NP (JJ Pre-operative) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (: -) (NP (VBN based) (NN chemoradiotherapy)) (ADVP (RB locally)) (VP (VBD advanced) (SBAR (S (NP (NP (JJ rectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN UICC-II/III)) (-RRB- -RRB-))) (VP (MD may) (ADVP (RB significantly)) (VP (VB reduce) (NP (JJ local) (NN tumour) (NN mass)))))))) |ET| |BS|8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404|ES| 10:1 14:1 18:1 19:1 124:1 491:1 997:1 1011:1 1985:1 1986:1 1989:1 2307:1 2308:1 2361:1 2804:1 2894:1 2895:1 2896:1 2897:1
-1 	|BT| (NP (NP (NNP Prevention) (NN rat) (NN liver) (NN fibrosis) (NN carcinogenesis) (NN coffee) (NN caffeine))) |ET| |BS|33:C04.697.098 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 652:D20.215.784.249 676:C06.552.630 819:D03.132.960.175|ES| 19:1 207:1 836:1 849:1 949:1 2386:1 2898:1 2899:1
-1 	|BT| (NP (NP (JJ Previous) (NN study)) (VP (VBN shown) (S (NP (NN decorin) (NN expression)) (VP (ADVP (RB significantly)) (VBD reduced) (NP (NP (JJ colorectal) (NN cancer) (NN tissue) (NN cancer) (NN cell)) (, ,) (NP (JJ genetic) (NN deletion) (NN decorin) (NN gene) (JJ sufficient) (NN cause) (JJ intestinal) (NN tumor) (NN formation) (NN mouse)) (, ,) (VP (VBG resulting) (NP (NN downregulation) (NN p21))) (, ,) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN kip1)) (-RRB- -RRB-))) (FRAG (NP (NN E-cadherin) (NN upregulation) (NN beta-catenin) (NN signaling)) (-LRB- -LSB-) (NP (NP (NN Bi)) (, ,) (NP (NN X))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 20:G03.495 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 69:G02.111.087.800 85:G02.111.087.225 98:A10 102:C04.588.274.476.411 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 549:G05.355.600.800.320 708:D12.776.395.650.750.625 820:D12.776.395.550.200.200|ES| 2:1 7:1 9:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 60:1 94:1 109:1 115:1 124:1 131:1 195:1 237:1 242:1 272:1 384:1 452:1 595:1 864:1 929:1 1059:1 1124:1 1126:1 1135:1 1373:1 1779:1 2267:1 2900:1 2901:1 2902:1 2903:1
-1 	|BT| (S (S (NP (JJ Previous) (NN work)) (VP (VBD showed) (NP (NN loss) (NN TIP30)))) (, ,) (ADVP (RB also)) (VP (VBN called) (S (NP (NN CC3))) (, ,) (NP (NP (JJ putative) (NN tumor) (NN suppressor)) (, ,) (NP (VBD increased) (NN incidence) (JJ hepatocellular) (NN carcinoma) (NN mouse)) (, ,) (NP (JJ clinical) (NN sample) (JJ human) (NN HCC) (NN tissue) (JJ aberrant) (NN expression) (NN TIP30))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 98:A10 104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249 434:E05.318.308.985.525.375 445:I03.946|ES| 2:1 5:1 7:1 19:1 32:1 36:1 47:1 52:1 84:1 115:1 132:1 272:1 303:1 304:1 441:1 700:1 835:1 918:1 1511:1 1546:1 1547:1 1725:1 2900:1 2904:1 2905:1
-1 	|BT| (S (NP (NNP Progastrin) (VBG targeting) (NN strategy)) (VP (VBP provide) (NP (JJ exciting) (NN prospect) (NN differentiation) (NN therapy) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 52:E02 74:G04.299.151 821:E05.318.760.500.750.500|ES| 17:1 18:1 19:1 130:1 215:1 616:1 711:1 1114:1 2906:1 2907:1 2908:1
-1 	|BT| (NP (NP (JJ Protective) (NN effect) (NN dioscin) (JJ alcohol-induced) (NN liver) (NN injury))) |ET| |BS|242:A03.620 751:D02.033.375 822:D02.033|ES| 19:1 75:1 836:1 2416:1 2672:1 2909:1 2910:1
-1 	|BT| (NP (NP (NN Protein) (NN kinase) (JJ potential) (JJ chemotherapeutic) (NN target) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 151:E02.319 823:D08.811.913.696.620.682.700.150.125|ES| 17:1 18:1 19:1 160:1 470:1 827:1 1762:1 2911:1
-1 	|BT| (S (NP (NN Pterostilbene)) (VP (VBZ inhibits) (NP (NP (NP (JJ colorectal) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (NP (NN colon) (NN carcinogenesis)) (PP (IN via) (NP (NN suppression) (JJ multiple) (NN signal) (NN transduction) (NN pathway) (JJ azoxymethane-treated) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 52:E02 122:C14.280.383 126:G02.111.087.800 132:D02.172.080 824:C04.834.020|ES| 10:1 14:1 17:1 19:1 52:1 113:1 207:1 383:1 596:1 615:1 649:1 859:1 1431:1 1725:1 2453:1 2793:1 2912:1 2913:1 2914:1 2915:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (JJ objective)) (VP (VBP investigate) (SBAR (IN whether) (S (NP (NP (NN polymorphism) (JJ putative) (NN influence) (NN fluorouracil/oxaliplatin) (NN activity)) (VBN associated) (JJ clinical) (NN outcome) (NN patient)) (VP (VBD advanced) (NP (NP (JJ colorectal) (NN cancer)) (VP (VBN treated) (NP (NP (JJ first-line) (NN oxaliplatin)) (, ,) (NP (JJ folinic) (NN acid)) (, ,) (NP (NN fluorouracil) (JJ palliative) (NN chemotherapy)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 151:E02.319 307:G05.365.795 415:F01.658.500 560:D03.383.742.698.875.404 825:D03.438.733.631.400.800.350.450 826:F01.752.609|ES| 2:1 17:1 18:1 19:1 84:1 104:1 120:1 169:1 221:1 399:1 459:1 495:1 547:1 687:1 691:1 867:1 918:1 997:1 1060:1 1099:1 1275:1 2490:1 2543:1 2916:1 2917:1 2918:1 2919:1 2920:1
-1 	|BT| (NP (NP (NP (NN Ras) (NN pathway) (NN activation) (JJ hepatocellular) (NN carcinoma) (JJ anti-tumoral) (NN effect)) (NP (VBN combined) (JJ sorafenib) (NN rapamycin) (FW vivo)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 104:C04.557.470.200.025.255 827:D02.540.505.760|ES| 19:1 75:1 164:1 225:1 303:1 304:1 378:1 383:1 1775:1 2063:1 2921:1 2922:1
-1 	|BT| (S (S (NP (JJ Regular) (NN aspirin) (NN use) (NN diagnosis)) (VP (VBD associated) (NP (JJR lower) (NN risk) (JJ colorectal) (JJ cancer-specific) (NN mortality)) (PP (IN among) (NP (NP (NN participant) (JJ primary) (NN tumor) (JJ overexpressed) (NN COX-2)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 0.39)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.20-0.76)))) (-RRB- -RRB-)))))) (, ,) (IN whereas) (S (NP (NN aspirin) (NN use)) (VP (VBD associated) (NP (JJR lower) (NN risk)) (PP (IN among) (NP (NP (JJ primary) (NN tumor) (JJ weak) (JJ absent) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 1.22)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.36-4.18)))) (-RRB- -RRB-))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 828:Z01.107.757.235|ES| 2:1 7:1 10:1 14:1 17:1 19:1 25:1 76:1 115:1 117:1 169:1 171:1 217:1 338:1 344:1 367:1 369:1 372:1 374:1 1037:1 1372:1 1659:1 2487:1 2508:1 2509:1 2511:1 2923:1 2924:1 2925:1 2926:1 2927:1 2928:1 2929:1 2930:1
-1 	|BT| (S (NP (NNS Results)) (NP (ADJP (FW vitro) (FW vivo)) (NN bioassay)) (ADVP (RB clearly)) (VP (VBP suggest) (SBAR (S (NP (NN beta-ionone)) (VP (MD could) (VP (VBD developed) (NP (NN prevention) (NN treatment) (NN colon) (NN cancer)))))))) |ET| |BS|52:E02 106:E05.091|ES| 18:1 19:1 113:1 216:1 378:1 546:1 702:1 796:1 908:1 1165:1 1474:1 2838:1 2931:1 2932:1
-1 	|BT| (FRAG (NP (NNS RESULTS)) (: :) (NP (NP (NN Liver) (NN tumor) (NN mass)) (NP (NP (NP (JJR lower) (NN pravastatin) (NN group)) (PRN (-LRB- -LRB-) (NP (NN PG)) (-RRB- -RRB-))) (NP (NP (NP (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NN CG)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN estimated) (NN number) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR <) (NP (CD 0.004)))) (-RRB- -RRB-))) (NP (NP (NN liver) (NN weight/body) (NN weight) (NN ratio)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (NP (QP (JJR <) (CD 0.04)))) (-RRB- -RRB-))))))) |ET| |BS|242:A03.620 515:C04.588.274.623 616:E05.318.780.074 653:C23.888.144 817:D02.455.426.559.847.638.930 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 104:1 117:1 289:1 312:1 646:1 710:1 836:1 2300:1 2399:1 2721:1 2804:1 2933:1 2934:1 2935:1 2936:1 2937:1 2938:1 2939:1 2940:1 2941:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN Silibinin) (NN feeding)) (VP (VBD showed) (NP (NP (ADJP (NP (JJ dose-dependent) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)) (JJR stronger)) (NN efficacy) (NN pretreatment)) (CC versus) (NP (NN posttreatment) (NNS regimen))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 532:E02.183|ES| 19:1 78:1 104:1 113:1 132:1 295:1 710:1 1881:1 1983:1 2304:1 2531:1 2533:1 2824:1 2942:1 2943:1 2944:1 2945:1
-1 	|BT| (S (NP (NNP Resveratrol)) (VP (VBZ interferes) (NP (NP (JJ N-nitrosodiethylamine-induced) (JJ hepatocellular) (NN carcinoma)) (JJ early) (JJ advanced) (NN stage) (JJ male) (JJ Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 303:1 304:1 849:1 997:1 1128:1 1129:1 1402:1 2603:1 2946:1 2947:1 2948:1
-1 	|BT| (S (S (NP (NN Rimonabant)) (VP (VBZ inhibits) (NP (JJ human) (NN colon) (NN cancer) (NN cell) (NN growth)))) (VP (VBZ reduces) (NP (NN formation) (JJ precancerous) (NN lesion) (NN mouse) (NN colon)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 341:C04.834|ES| 18:1 19:1 36:1 43:1 52:1 94:1 102:1 113:1 142:1 615:1 1130:1 1131:1 2949:1
-1 	|BT| (NP (NP (NN Role) (NN Fas/FasL) (NN pathway) (NN combination) (NN therapy) (NN interferon-alpha) (NN fluorouracil) (JJ hepatocellular) (NN carcinoma) (NN vitro))) |ET| |BS|15:F01.829.316.616 104:C04.557.470.200.025.255 356:D12.644.276.374.440.890.250 560:D03.383.742.698.875.404 618:E02.186|ES| 19:1 130:1 216:1 303:1 304:1 383:1 530:1 1198:1 2187:1 2919:1 2950:1
-1 	|BT| (NP (NP (NNP Saffron)) (: :) (NP (JJ potential) (NN candidate) (JJ novel) (JJ anticancer) (NN drug) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|67:D26 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 701:B01.650.940.800.575.100.549.500|ES| 19:1 104:1 191:1 303:1 304:1 827:1 891:1 1243:1 1880:1 2951:1
-1 	|BT| (NP (NP (NNP Sesamin)) (, ,) (NP (JJ lipid-soluble) (NN lignan)) (, ,) (S (NP (CD one) (NN agent)) (VP (VBZ belongs) (NP (SBAR (S (NP (NP (NN class) (NNS phytoestrogens)) (, ,) (NP (NP (VBN isolated) (NN sesame)) (PRN (-LRB- -LRB-) (NP (NN Sesamum) (NN indicum)) (-RRB- -RRB-))) (, ,)) (VP (VBN linked) (NP (NN prevention) (NN hyperlipidemia))))) (, ,) (NP (NP (NN hypertension)) (, ,) (NP (NN carcinogenesis) (JJ unknown) (NN mechanism))))))) |ET| |BS|33:C04.697.098 621:D02.455.426.559.389.140.450 659:D10 766:C18.452.584.500.500 830:B01.650.940.800.575.100.583.690.750 831:D27.505.696.399.472.277.540.500 832:C14.907.489|ES| 2:1 10:1 14:1 19:1 162:1 207:1 728:1 1010:1 1363:1 1474:1 1653:1 2182:1 2313:1 2692:1 2814:1 2952:1 2953:1 2954:1 2955:1 2956:1 2957:1 2958:1 2959:1
-1 	|BT| (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (JJ molecular) (NN therapy) (JJ non-small-cell) (NN lung) (NN cancer))) |ET| |BS|52:E02 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 375:Z01.639.100|ES| 18:1 19:1 130:1 161:1 327:1 328:1 487:1 860:1 861:1 862:1 2960:1
-1 	|BT| (S (NP (NN Simvastatin)) (VP (VP (VBZ induces) (NP (NN apoptosis) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft))) (, ,) (VP (VBZ attenuates) (NP (JJ colitis-associated) (NN colon) (NN cancer) (NN mouse))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900|ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1
-1 	|BT| (S (NP (NN Sodium) (NN alginate)) (VP (VBZ prevents) (NP (NN progression) (JJ non-alcoholic) (NN steatohepatitis) (NN liver) (NN carcinogenesis) (JJ obese) (JJ diabetic) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 33:C04.697.098 242:A03.620 509:C06.552.241.519 564:C18.654.726.500|ES| 19:1 48:1 52:1 207:1 836:1 1791:1 2069:1 2468:1 2718:1 2962:1 2963:1 2964:1
-1 	|BT| (S (NP (NN Sulindac) (NNS NSAIDs)) (VP (ADVP (RB widely)) (NP (VBN studied) (NP (JJ potential) (JJ chemopreventive) (NN agent) (NN colon) (NN cancer))))) |ET| |BS|251:D02.455.426.559.847.486.875 796:D27.505.696.663.850.014.040.500 833:D27.505.696.706.018|ES| 18:1 19:1 113:1 401:1 728:1 827:1 1946:1 2369:1 2965:1 2966:1
-1 	|BT| (S (NP (NP (NN Supplementation) (JJ branched-chain) (NN amino) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BCAA)) (-RRB- -RRB-))) (VP (VBZ reduces) (NP (NP (NN risk) (NN liver) (NN cancer) (JJ cirrhotic) (NN patient)) (NP (JJ obese) (, ,) (NP (JJ associated) (NN improvement) (NN insulin) (NN resistance)))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500|ES| 2:1 10:1 14:1 18:1 19:1 120:1 142:1 169:1 171:1 836:1 1094:1 1275:1 2189:1 2359:1 2360:1 2364:1 2468:1 2967:1 2968:1 2969:1
-1 	|BT| (S (NP (NP (NP (NN Suppression) (JJ early) (NN stage) (JJ neoplastic) (NN transformation)) (JJ two-stage) (NN chemical) (NN hepatocarcinogenesis) (NN model)) (: :) (S (NP (NP (NN supplementation) (NN vanadium)) (, ,) (NP (JJ dietary) (NN micronutrient)) (, ,) (NP (NN limit) (NN cell) (NN proliferation))) (VP (VBZ inhibits) (NP (NP (NN formation) (NN 8-hydroxy-2)) ('' ')))) (: -)) (VP (NNS deoxyguanosines) (NP (NN DNA) (NNS strand-breaks) (NN liver) (JJ sprague-dawley) (NN rat)))) |ET| |BS|20:G03.495 32:C04.697.098.500 122:C14.280.383 183:G04.299.233.750 242:A03.620 595:G07.203.650.240 769:B01.050.150.900.649.865.635.505.700.750 834:D27.505.696.377.605.555 835:D27.505.696.377.605 836:G05.355.180.210 837:D01.268.556.920 838:E05.599.495|ES| 2:1 19:1 43:1 72:1 94:1 104:1 299:1 615:1 666:1 836:1 849:1 893:1 900:1 1128:1 1129:1 1384:1 2124:1 2567:1 2594:1 2797:1 2970:1 2971:1 2972:1 2973:1 2974:1 2975:1 2976:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (NP (VBN indicated) (NN nifuroxazide)) (VP (MD could) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN tumor) (NN metastasis)) (S (VP (VBG mediating) (NP (NP (NN Stat3)) (NN pathway))))))) (VP (MD might) (NP (JJ therapeutic) (JJ potential) (NN treatment) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383|ES| 2:1 7:1 19:1 101:1 245:1 383:1 541:1 546:1 761:1 798:1 806:1 827:1 908:1 1370:1 1537:1 1538:1 1541:1 2646:1 2820:1 2977:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP provide) (SBAR (S (NP (NP (NN evidence) (NN plant) (NN flavonoid) (NN fisetin)) (VP (VBP induce) (NP (NN apoptosis)))) (VP (VBP suppress) (NP (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN inhibition) (NN COX2)) (: -) (NP (NN Wnt/EGFR/NF-kappaB-signaling) (NN pathway)))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 43:F01.145.544 45:G07.700.320.249 147:G02.149.115.800.925 210:D12.776.260.600 328:B01.650 534:D03.383.663.283.266.450|ES| 2:1 18:1 19:1 38:1 89:1 94:1 102:1 103:1 113:1 243:1 383:1 711:1 1098:1 1537:1 1538:1 1886:1 2441:1 2978:1 2979:1 2980:1
-1 	|BT| (S (NP (VBN Targeted) (NN disruption) (JJ Nemo-like) (NN kinase)) (VP (VBZ inhibits) (NP (NN tumor) (NN cell) (NN growth) (JJ simultaneous) (NN suppression) (NN cyclin) (NN D1) (NN CDK2) (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|8:C04 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 215:D12.644.360.262.150.100 469:D08.811.913.696|ES| 7:1 19:1 36:1 94:1 102:1 303:1 304:1 470:1 615:1 743:1 744:1 1602:1 2453:1 2981:1 2982:1 2983:1 2984:1
-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP investigate) (NP (NP (NP (NP (JJ molecular) (NN mechanism) (JJ chemopreventive) (NN effect)) (JJ folic) (NN acid) (NN tributyrin)) (ADVP (RB alone))) (NN combination) (NN rat) (NN hepatocarcinogenesis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 624:D27.505.696.706.018 839:D03.438.733.631.400|ES| 19:1 75:1 131:1 161:1 162:1 241:1 459:1 530:1 691:1 849:1 900:1 1275:1 1567:1 1946:1 2985:1 2986:1
-1 	|BT| (S (NP (DT The) (NN cyclooxygenase-2) (-LRB- -LRB-) (NN COX-2) (-RRB- -RRB-) (NN inhibitor) (NN celecoxib)) (VP (VBN approved) (NP (NP (NN drug) (NN clinic) (NN colon) (NN cancer) (NN chemoprevention)) (VP (VBN tested) (NP (NP (JJ chemopreventive) (JJ therapeutic) (NN efficacy)) (JJ various) (JJ clinical) (NN trial)))))) |ET| |BS|12:Z01.542.049 52:E02 67:D26 253:E02.319.162 349:D27.505.519.389.310.500 683:D27.505.519.389.310 684:D02.065.884.247 840:E01.789.800 841:E05.318.760.250.500 842:N02.278.035|ES| 10:1 14:1 18:1 19:1 61:1 76:1 84:1 113:1 191:1 380:1 541:1 691:1 870:1 1096:1 1946:1 2304:1 2343:1 2807:1 2987:1 2988:1 2989:1
-1 	|BT| (S (NP (DT The) (NNS data)) (VP (VBP provide) (NP (JJ additional) (NN evidence) (JJ potential) (NN use) (NN roxithromycin) (NN treatment) (JJ hepatocellular) (NN carcinoma) (NN prevention)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 843:D02.540.576.500.992.630|ES| 19:1 38:1 303:1 304:1 546:1 691:1 711:1 793:1 827:1 980:1 1474:1 1659:1 2990:1
-1 	|BT| (NP (NP (NP (DT The) (JJ Dual) (NN Inhibition) (NN RNA) (NN Pol)) (SBAR (S (NP (PRP I)) (NP (NN Transcription) (NNP PIM) (NN Kinase) (NNP New) (JJ Therapeutic) (NNP Approach) (NNP Treat) (NNP Advanced) (NNP Prostate) (NNP Cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 52:E02 209:G02.111.087.847 844:D08.811.913.696.445.735.270.750|ES| 19:1 469:1 515:1 691:1 1197:1 1412:1 1919:1 2280:1 2350:1 2703:1 2991:1 2992:1 2993:1 2994:1 2995:1 2996:1 2997:1
-1 	|BT| (S (NP (DT The) (JJ oncogenic) (NN kinase) (NN inhibitor) (NN sorafenib)) (ADVP (RB significantly)) (VP (VB prolong) (SBAR (S (NP (JJ median) (NN survival) (NN patient)) (VP (VBD advanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (, ,) (SBAR (IN although) (S (NP (NN response) (JJ disease-stabilizing) (JJ cytostatic)) (NP (QP (RB rather) (CD one)) (NN tumor) (NN regression))))))))) |ET| |BS|8:C04 50:M01.643 96:I03.784 104:C04.557.470.200.025.255 279:D27.888.569.100 288:C23.550.288 469:D08.811.913.696 845:D27.888.569.199 846:F01.393.784|ES| 2:1 7:1 10:1 14:1 19:1 120:1 124:1 274:1 303:1 304:1 380:1 441:1 470:1 494:1 691:1 953:1 997:1 1010:1 1170:1 1592:1 2063:1 2998:1 2999:1 3000:1 3001:1 3002:1
-1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ allows) (SBAR (S (NP (NN u)) (VP (VBP conclude) (SBAR (S (NP (JJ diosmin) (JJ dietary) (NN supplement)) (, ,) (VP (MD could) (VP (VBN used) (S (NP (JJ chemopreventive) (NN agent)) (VP (VBP prevent) (NP (NN hepatocarcinogenesis))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 557:D02.241.081.069.600.150 715:D03.383.663.283.266.450.260.222 847:G07.203.300.456|ES| 2:1 19:1 131:1 476:1 691:1 728:1 733:1 900:1 908:1 1307:1 1946:1 1968:1 2243:1 2594:1 2695:1 3003:1 3004:1
-1 	|BT| (NP (NP (NP (DT The) (JJ present) (NN study) (NN offer) (NN strategy) (JJ novel) (NN CUR) (NN analogue)) (, ,) (PRN (-LRB- -LRB-) (NP (NN 1E) (CD ,4) (NN E)) (-RRB- -RRB-)) (NP (NP (NP (NN -1,5-bis) (-LRB- -LRB-) (NN 2-bromophenyl) (-RRB- -RRB-) (NN penta-1,4-dien-3-one)) (PRN (-LRB- -LRB-) (NP (NN GL63)) (-RRB- -RRB-))) (, ,) (NP (VBN used) (JJ potential) (NP (NP (JJ therapeutic) (NN agent) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (ADVP (FW vitro) (FW vivo))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 131:1 216:1 303:1 304:1 378:1 441:1 476:1 541:1 691:1 728:1 827:1 891:1 1042:1 1114:1 1307:1 1380:1 3005:1 3006:1 3007:1 3008:1 3009:1 3010:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VBP investigate) (FRAG (NP (NP (JJ chemopreventive) (NN action) (JJ possible) (NN mechanism) (NN saffron) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN liver) (NN cancer) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 701:B01.650.940.800.575.100.549.500|ES| 10:1 14:1 18:1 19:1 162:1 409:1 459:1 691:1 836:1 849:1 1359:1 1497:1 1875:1 1946:1 1952:1 2013:1 2523:1 3011:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN study)) (VP (VBP evaluate) (NP (NP (NP (JJ anticancer) (NN potency) (NN mechanism) (JJ novel) (NN difluorodiarylidenyl) (NN piperidone)) (PRN (-LRB- -LRB-) (NP (NN H-4073)) (-RRB- -RRB-))) (S (NP (NP (NN N-hydroxypyrroline) (NN modification)) (PRN (-LRB- -LRB-) (NP (NN HO-3867)) (-RRB- -RRB-))) (NP (JJ human) (JJ ovarian) (NN cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 179:D01.248.497.300.459.700 225:E05.337 259:D12.776.395.240.150.500 848:D03.383.621.808|ES| 10:1 14:1 18:1 19:1 36:1 131:1 162:1 691:1 890:1 891:1 1763:1 1880:1 2374:1 2796:1 3011:1 3012:1 3013:1 3014:1 3015:1 3016:1
-1 	|BT| (NP (NP (NP (DT The) (NN rate) (NN proliferation) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN reduced) (JJ treated) (NN gamma-secretase) (NN inhibitor) (NN dibenzazepine)) (VP (VBP inhibit) (NP (NP (NN Notch) (NN signaling) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD directed) (NP (NN Notch))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 117:D13.150.650.700 122:C14.280.383 125:D08.811.277.656.300.032 212:E01.370.225.500.385.500 792:A11.251.210.190.475|ES| 18:1 19:1 36:1 41:1 94:1 113:1 195:1 256:1 299:1 380:1 452:1 515:1 691:1 750:1 1099:1 1370:1 1866:1 3017:1 3018:1 3019:1 3020:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBD indicated) (SBAR (S (NP (NN 6-MSITC)) (VP (VBD exerted) (NP (NP (NP (JJ chemopreventive) (NN effect)) (JJ present) (JJ short-term) (NN colon) (NN carcinogenesis) (NN bioassay)) (, ,) (NP (NP (NN alteration) (NN cell) (NN proliferation) (NN activity) (NN drug)) (VP (VBG metabolizing) (NP (NN enzyme) (NN level)))))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 67:D26 106:E05.091 212:E01.370.225.500.385.500 624:D27.505.696.706.018 649:E01.370.225.124.200 849:G08.686.785.760.769.490.500|ES| 2:1 19:1 75:1 94:1 101:1 113:1 191:1 207:1 249:1 299:1 399:1 691:1 951:1 1307:1 1541:1 1946:1 2102:1 2388:1 2931:1 3021:1 3022:1 3023:1
-1 	|BT| (S (NP (DT The) (JJ selective) (NN EGFR) (NN inhibitor) (NN Gefitinib)) (VP (VBD found) (S (VP (VBP prevent) (NP (NN hepatocarcinogenesis) (NN rat) (JJ cirrhotic) (NN liver)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 37:1 187:1 380:1 691:1 733:1 836:1 849:1 900:1 1749:1 2968:1 3024:1
-1 	|BT| (S (NP (DT The) (NN study)) (VP (VBD suggested) (SBAR (S (NP (NN HO-3867)) (VP (MD may) (NP (NP (JJ useful) (JJ safe) (JJ effective) (JJ anticancer) (NN agent)) (JJ ovarian) (NN cancer) (NN therapy))))))) |ET| |BS|52:E02|ES| 18:1 19:1 130:1 131:1 491:1 691:1 728:1 925:1 1036:1 1639:1 1763:1 1880:1 2737:1 3016:1
-1 	|BT| (S (NP (DT The) (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (MD may) (SBAR (S (NP (JJ unique) (NN property) (VBG providing) (NN protection) (JJ DENA-induced) (JJ oxidative) (NN stress)) (VP (MD could) (VP (VB contribute) (NP (NN chemoprevention) (JJ experimental) (NN hepatocarcinogenesis)))))))) |ET| |BS|253:E02.319.162 554:D02.654.442.200 716:G03.495.710 803:D01.248.497.158.845 804:D09.698|ES| 19:1 263:1 450:1 491:1 691:1 841:1 870:1 900:1 908:1 1469:1 2522:1 2583:1 2734:1 2839:1 2840:1 2841:1 2842:1 3025:1 3026:1
